Sarepta (SRPT) Has 10% Pull Back Risk on SRP-5051 Hold - Raymond James Reiterates Stock at Market Perform
Tweet Send to a Friend
Raymond James analyst Danielle Brill reiterated a Market Perform rating on Sarepta Therapeutics (NASDAQ: SRPT), following the company's announcement SRP-5051 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
